EXPLICYTE

Domain Therapeutics and Explicyte are multi-year partners and are collaborating on different aspects of Domain’s drug discovery. Since 2022, Explicyte and Domain are part of the consortium built on the RHU CONDOR Project to address precision medicine and immunotherapy of sarcoma. Because of its expertise in tumor and peripheral multiparametric profiling for immuno-oncology biomarker discovery and development, Explicyte and Domain pursue their collaboration to characterize and select the best candidates from undisclosed GPCR targeting programs with a potential of first-in-class drugs, as well as developing the biomarker strategy enabling the selection of patient according to the multiplexed-signature.